iconstar paper   HIV Articles  
Back grey arrow rt.gif
 
 
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
 
 
  https://clinicaltrials.gov/ct2/show/NCT04583423
 
Brief Summary:
 
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with respect to the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.
 

study

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org